Literature DB >> 21376049

CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins.

Marianne Ruhl1, Torben Knuschke, Kevin Schewior, Lejla Glavinic, Christoph Neumann-Haefelin, Dae-In Chang, Marina Klein, Falko M Heinemann, Hannelore Tenckhoff, Manfred Wiese, Peter A Horn, Sergei Viazov, Ulrich Spengler, Michael Roggendorf, Norbert Scherbaum, Jacob Nattermann, Daniel Hoffmann, Jörg Timm.   

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) acquires mutations that allow it to escape the CD8+ T-cell response, although the extent to which this process contributes to viral evolution at the population level is not clear. We studied viral adaptation using data from a large outbreak of HCV genotype 1b infection that occurred among women immunized with contaminated immunoglobulin from 1977 to 1978.
METHODS: The HCV nonstructural protein coding regions NS3-NS5B were sequenced from 78 patients, and mutations were mapped according to their location inside or outside previously described CD8+ T-cell epitopes. A statistical approach was developed to identify sites/regions under reproducible selection pressure associated with HLA class I.
RESULTS: The frequency of nonsynonymous mutations was significantly higher inside previously described CD8+ T-cell epitopes than outside-particularly in NS3/4A and NS5B. We identified new regions that are under selection pressure, indicating that not all CD8+ T-cell epitopes have been identified; 6 new epitopes that interact with CD8+ T cells were identified and confirmed in vitro. In some CD8+ T-cell epitopes mutations were reproducibly identified in patients that shared the relevant HLA allele, indicating immune pressure at the population level. There was statistical support for selection of mutations in 18 individual epitopes. Interestingly, 14 of these were restricted by HLA-B allele.
CONCLUSIONS: HLA class I-associated selection pressure on the nonstructural proteins and here predominantly on NS3/4A and NS5B promotes evolution of HCV. HLA-B alleles have a dominant effect in this selection process. Adaptation of HCV to the CD8+ T-cell response at the population level creates challenges for vaccine design.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376049     DOI: 10.1053/j.gastro.2011.02.060

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

1.  Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Authors:  Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

Review 2.  Update on hepatitis C virus-specific immunity.

Authors:  Donatella Ciuffreda; Arthur Y Kim
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

3.  Genomic variability of within-host hepatitis C variants in acute infection.

Authors:  Chaturaka Rodrigo; Preston Leung; Andrew R Lloyd; Rowena A Bull; Fabio Luciani; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Andrea L Cox; William Osburn; Arthur Y Kim; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Janke Schinkel; Maria Prins; Margaret Hellard; Auda A Eltahla
Journal:  J Viral Hepat       Date:  2019-01-22       Impact factor: 3.728

4.  Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.

Authors:  Susanne Ziegler; Kathrin Skibbe; Andreas Walker; Xiaoyu Ke; Falko M Heinemann; Andreas Heinold; Juk Yee Mok; Wim J E van Esch; Dongliang Yang; Matthias Wölfl; Jörg Timm
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

5.  Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope.

Authors:  Marianne Ruhl; Patrick Chhatwal; Heiko Strathmann; Thomas Kuntzen; Dorothea Bankwitz; Kathrin Skibbe; Andreas Walker; Falko M Heinemann; Peter A Horn; Todd M Allen; Daniel Hoffmann; Thomas Pietschmann; Jörg Timm
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

6.  Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus.

Authors:  Katja Pfafferott; Pooja Deshpande; Elizabeth McKinnon; Shahzma Merani; Andrew Lucas; David Heckerman; Simon Mallal; Mina John; Silvana Gaudieri; Michaela Lucas
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

7.  Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1.

Authors:  Rafael Sanjuán; Miguel R Nebot; Joan B Peris; José Alcamí
Journal:  PLoS Biol       Date:  2013-04-02       Impact factor: 8.029

8.  Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.

Authors:  Rowena A Bull; Fabio Luciani; Kerensa McElroy; Silvana Gaudieri; Son T Pham; Abha Chopra; Barbara Cameron; Lisa Maher; Gregory J Dore; Peter A White; Andrew R Lloyd
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

9.  Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Authors:  Ola Weiland; Gustaf Ahlén; Helmut Diepolder; Maria-Christina Jung; Sepideh Levander; Michael Fons; Iacob Mathiesen; Niranjan Y Sardesai; Anders Vahlne; Lars Frelin; Matti Sällberg
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

10.  Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses.

Authors:  Jonathan R Honegger; Seungtaek Kim; Aryn A Price; Jennifer A Kohout; Kevin L McKnight; Mona R Prasad; Stanley M Lemon; Arash Grakoui; Christopher M Walker
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.